Cargando…

Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy

Detalles Bibliográficos
Autores principales:	Rushworth, David, Mi, Tiejuan, Olivares, Simon, Carrero, Rosa Santana, Yang, Ge, Najjar, Amer, Cooper, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991294/ http://dx.doi.org/10.1186/2051-1426-1-S1-P32

Ejemplares similares

Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
por: Park, Anthony K, et al.
Publicado: (2015)

Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy
por: Jonnalagadda, Mahesh, et al.
Publicado: (2013)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
por: Dabiri, Hamed, et al.
Publicado: (2023)

578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
por: Tran, Nikki, et al.
Publicado: (2020)

925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy
por: Trottier, Caitlin, et al.
Publicado: (2021)

Single cell metrics of the efficacy of CAR T cells
por: Romain, Gabrielle, et al.
Publicado: (2015)

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma
por: Ladd, Alden, et al.
Publicado: (2015)

A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target
por: Santoro, Stephen P, et al.
Publicado: (2013)

P72. Transgenic expression of a chimeric signaling receptor to facilitate T cell costimulation in the tumour environment
por: Schlenker, R, et al.
Publicado: (2014)

1098. Norovirus Infection in Cancer Patients Undergoing Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T)
por: Kondapi, Divya S, et al.
Publicado: (2020)

1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)

Quantitative single-cell characterization of CAR+ T cell effector functions
por: Liadi, Ivan, et al.
Publicado: (2013)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)

Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis
por: Priceman, Saul, et al.
Publicado: (2015)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Cloning of a synthetic chimeric gene containing recombinant Mycoplasma hyopneumoniae antigens for expression in Pichia pastoris
por: Gomes, Charles, et al.
Publicado: (2014)

Development of chimeric antigen receptor-redirected T cell therapy targeting L1-CAM in ovarian cancer
por: Hong, Hao, et al.
Publicado: (2013)

Functional and molecular characterization of single serial killer CAR+ T cells demonstrates adaptive modification of behavior and fate based on tumor cell density
por: Varadarajan, Navin, et al.
Publicado: (2014)

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of V(L) and V(H) Domains Targeting CD123(+) Tumors
por: Thokala, Radhika, et al.
Publicado: (2016)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
por: Verburg-Baltussen, E. J., et al.
Publicado: (2022)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule
por: Byrd, Tiara, et al.
Publicado: (2014)

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
por: Walter Georgi, Thomas, et al.
Publicado: (2023)

Feasibility and safety of cCD20 RNA CAR-bearing T cell therapy for the treatment of canine B cell malignancies
por: Smith, Jenessa B, et al.
Publicado: (2015)

Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
por: Jena, Bipulendu, et al.
Publicado: (2013)

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021)

P17-15. Immunogenicity studies of chimeric yellow fever 17D viruses carrying HIV-1 p24 antigen
por: Franco, D, et al.
Publicado: (2009)

Enhanced glycolytic metabolism is associated with exhaustion and poor antitumor efficacy in a xenograft model of chimeric antigen receptor T cell therapy for sarcoma
por: Long, Adrienne H, et al.
Publicado: (2013)

P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
por: Zhang, Xian, et al.
Publicado: (2023)

Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors
por: Highfill, Steven L, et al.
Publicado: (2013)

GUCY2C-targeted chimeric antigen receptor expressing T cells extend survival in a therapeutic mouse model of metastatic colorectal cancer
por: Magee, Michael S, et al.
Publicado: (2013)

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis
por: Hunter, Bradley D., et al.
Publicado: (2022)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kk0lme9mjuqqsdf6hofo2hvr1s